Apotex expected to fetch $10-billion valuation as drugmaker files to go public on TSX
Apotex Health Corp. has filed for an initial public offering on the Toronto Stock Exchange, aiming for a valuation exceeding $10 billion. The Canadian generic drug maker is expected to raise between $500 million and $1 billion from the offering. Proceeds will be used to repay existing debt incurred during a recapitalization effort last year.
- ▪Apotex is expected to become Canada's most valuable life-sciences company with a valuation over $10 billion.
- ▪The company generated $1.3 billion in adjusted operating earnings last year on $3.5 billion of sales.
- ▪The IPO aims to raise between $500 million and $1 billion to repay indebtedness under its credit facilities.
The Globe and Mail publishes from Canada and files mainly under world. We currently carry 1,936 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Globe and Mail |
| Canonical URL | https://www.theglobeandmail.com/business/economy/article-apotex-expected-to-fetch-10-billion-valuation-as-drugmaker-files-to-go/ |
| Publication time | Thu, 28 May 2026 19:15:51 +0000 |
| Retrieval time | 2026-05-28T19:23:01.382Z |
| Last seen | 2026-05-28T19:23:01.382Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 4uqn5pGY1XOZ |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Open this photo in gallery:FDA-related holdups, court documents say, forced Apotex to repeat and recertify its studies, delaying the journey of the drugs to market.Peter Power/The Globe and MailShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountApotex Health Corp. has filed to go public on the Toronto Stock Exchange in an offering that is expected to establish the Canadian generic drug maker as Canada’s most valuable life-sciences company.Apotex is expected to raise between $500-million and $1-billion in in the deal, said a source familiar with the matter.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
